Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%
Market cap
$6.7B
P/E
102×
Fwd P/E
−108×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

14.49 19.03 38.02 130.02
P/S ratio
3.26 3.12 3.76 5.25
P/FCF ratio
10.09 9.57 26.57 39.30
P/Operating CF
48.71 27.10 (35.46) 60.28
P/B ratio
2.86 2.53 3.36 4.84
EV/Sales
2.71 2.42 4.40 5.76
EV/EBITDA
10.63 12.73 28.20 43.12
EV/FCF
8.41 7.43 31.08 43.10
Current Ratio
3.67 3.55 2.27 2.30
Net Debt/EBITDA
(11.44) (21.30) (61.92) 10.63
Debt/Equity
0.00 0.00 0.86 0.83
Earnings Yield
6.90% 5.25% 2.63% 0.77%
Free Cash Flow Yield
9.91% 10.45% 3.76% 2.54%
Free Cash Flow per Share
0.51 1.04 (1.02) 0.82
Book value per Share
10.50 11.05 10.54 10.83
Free Cash Flow
84.36 171.14 (169.82) 137.04
EV/EBIT
11.52 14.09 35.83 81.86
Other line items

Show all line items

Columns are period end dates